Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.02 GBP
−2.23 M GBP
1.14 M GBP
79.49 M
About FUSION ANTIBODIES PLC ORD GBP0.04
Sector
Industry
CEO
Adrian Kinkaid
Website
Headquarters
Dunmurry
Founded
2000
ISIN
GB00BDQZGK16
FIGI
BBG00JDYBTZ5
Fusion Antibodies Plc engages in research, development, and manufacturing recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The firm also offers antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company was founded by Michael Townsley and James Anthony Johnston on November 29, 2000 and is headquartered in Dunmurry, the United Kingdom.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of FAB is 7.10 GBX — it hasn't changed in the past 24 hours. Watch FUSION ANTIBODIES PLC ORD GBP0.04 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange FUSION ANTIBODIES PLC ORD GBP0.04 stocks are traded under the ticker FAB.
FAB stock has risen by 5.20% compared to the previous week, the month change is a 59.09% rise, over the last year FUSION ANTIBODIES PLC ORD GBP0.04 has showed a 57.56% increase.
FAB stock is 5.88% volatile and has beta coefficient of −2.24. Track FUSION ANTIBODIES PLC ORD GBP0.04 stock price on the chart and check out the list of the most volatile stocks — is FUSION ANTIBODIES PLC ORD GBP0.04 there?
Today FUSION ANTIBODIES PLC ORD GBP0.04 has the market capitalization of 6.72 M, it has increased by 6.06% over the last week.
Yes, you can track FUSION ANTIBODIES PLC ORD GBP0.04 financials in yearly and quarterly reports right on TradingView.
FUSION ANTIBODIES PLC ORD GBP0.04 is going to release the next earnings report on May 28, 2025. Keep track of upcoming events with our Earnings Calendar.
FUSION ANTIBODIES PLC ORD GBP0.04 revenue for the last half-year amounts to 1.21 M GBX, despite the estimated figure of 1.20 M GBX. In the next half-year revenue is expected to reach 800.00 K GBX.
FAB net income for the last half-year is −758.00 K GBP, while the previous report showed −869.00 K GBP of net income which accounts for 12.77% change. Track more FUSION ANTIBODIES PLC ORD GBP0.04 financial stats to get the full picture.
No, FAB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. FUSION ANTIBODIES PLC ORD GBP0.04 EBITDA is −1.51 M GBP, and current EBITDA margin is −181.16%. See more stats in FUSION ANTIBODIES PLC ORD GBP0.04 financial statements.
Like other stocks, FAB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade FUSION ANTIBODIES PLC ORD GBP0.04 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So FUSION ANTIBODIES PLC ORD GBP0.04 technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating FUSION ANTIBODIES PLC ORD GBP0.04 stock shows the neutral signal. See more of FUSION ANTIBODIES PLC ORD GBP0.04 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.